Lower Urine Tenofovir Concentrations among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/77071

Title:	Lower Urine Tenofovir Concentrations among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
Authors:	Kelly A. Johnson Xin Niu David V. Glidden Jose R. Castillo-Mancilla Jenna Yager Samantha Mawhinney Mary Morrow Hideaki Okochi Tim R. Cressey Paul K. Drain Monica Gandhi Peter L. Anderson Matthew A. Spinelli
Authors:	Kelly A. Johnson Xin Niu David V. Glidden Jose R. Castillo-Mancilla Jenna Yager Samantha Mawhinney Mary Morrow Hideaki Okochi Tim R. Cressey Paul K. Drain Monica Gandhi Peter L. Anderson Matthew A. Spinelli
Keywords:	Medicine
Issue Date:	1-Jul-2021
Abstract:	From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.
URI:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85112588480&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/77071
ISSN:	23288957
Appears in Collections:	CMUL: Journal Articles

Files in This Item:

There are no files associated with this item.